JERUSALEM, September 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference to be held on September 8, 2017 at the Millennium Broadway Hotel & Conference Center

JERUSALEM, August 21, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the

JERUSALEM, August 16, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share.

JERUSALEM, Aug. 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, today reported financial results for the six months ended June 30, 2017.

JERUSALEM, July 27, 2017 /PRNewswire/ --  Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ (AP) platform technology, announces the promotion of Nadav Navon, Ph.D., Executive Vice

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill [ TM ]  platform technology, announces that the Patent Registry Intellectual Property Department of Hong

JERUSALEM, July 19, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Patent Registry Intellectual Property Department of Hong Kong has

JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.

Intec Pharma Ltd. (Nasdaq:NTEC)(TASE:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the company will participate at the following two upcoming June conferences: LD Micro Invitational Date and

JERUSALEM, May 24, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the United States Patent and Trademark Office has granted the Company patent